Erved compared to the control Imiquimod 99011-02-6 group at CB STM. However, in the treated groups CBlithium STZlithium and there were no significant changes Changes in the relative number of CB-CR group, w Were treated while in the group there is a significant STZlithium erh Increase the CR, in terms of the LTM STZ . In addition, treated animals did CBphenserine showsignificant differences in CR compared to the CB control group On and STZphenserine MODIFIED nothing in the CR to the STM. CBphenserine STZphenserine treated groups and no change compared to contr The CR, w While in the CB group STZphenserine there was a significant increase in CR at the LTM to the STC. However, was CBmemantine STZmemantine and treated groups not significantly Changed in comparison to the CR command at the CB and STM LTM.While in STZmemantine CR group was significantly h Forth treated as in STZ rats STMand LTM. Closing Lich CBpioglitazone STZpioglitazone and VER changed Not materially affect the CR-controlled comparison At the CB STM and LTM, w Obtained during STZpioglitazone Ht fa Is significant compared to rats given STZ STM and LTM in CR. 2.3. The base rate per total GSK3 GSK3 and unskilled trained animals vs. CB ICV P values GSK3 and total GSK3 in the hippocampus and PFC of rats not registered Born CB ICV were the base, and were entered compared with those from rats Born CB ICV. The levels of GSK3 p does not enter animals Were born and educated slightly or significantly increased in the hippocampus and PFC ht Were. 2.4. Effects of lithium, phenserine, memantine and pioglitazone on the phosphorylation and hippocampus and PFC GSK3in total STZ-treated rats formed 2.4.1. The quantitative analysis of the hippocampus immunoblots indicated that the level of the hippocampus were significantly decremented p GSK3 in the STZ group compared to the control group CB. Lithium, memantine has phenserine treatment and pioglitazone no significant differences in levels between the STZ-treated and control animals GSK3 CB p. However, with the exception of memantine increased for all other drugs fa P GSK3 levels are significantly associated to STZ treatment in the hippocampus.
Was also not significantly treatments Changes the total levels of GSK3 in STZ-treated animals for CB or STZ groups. In the hippocampus was significantly GSK3/GSK3 P fell STZmemantine STZ-treated rats and relation to CB showed, however, controlled lithium, phenserine and pioglitazone no differenceswith CB group On. The ratio Ratio p GSK3/GSK3 ratio Ratio significantly in ICVSTZall other drugs compared to ICV STZ treatment increased Ht. 2.4.2. Pr Frontal cortex Irinotecan 97682-44-5 Western blot showed that the values of p GSK3 PFC were significantly STZ rats compared with the values of the controlled CB decremented. However, in the hippocampus lithium the only drug that has a significant Erh Increase of GSK3 p STZ-treated rats compared with STZ alone was generated. Phenserine treatment had been treated with pioglitazone and memantine has no effect on the levels of GSK3 p-STZ group relative to STZ alone. Neither drug Se treatment does not affect the total levels of GSK3 in the group with CB or STZ STZ-treated patients. But that ratio Ratio p GSK3/GSK3 PFC-money ratio was ma Major role in rats with STZ-treated group decreased compared to the CB. given that GSK3 plays a role the key in the pathogenesis of AD, the Gang.